Skip to main content
. Author manuscript; available in PMC: 2011 Mar 25.
Published in final edited form as: J Neurosurg. 2009 Mar;110(3):572–582. doi: 10.3171/2008.7.JNS08475

Fig. 4.

Fig. 4

A: Two representative dot plots showing CD45 and CD11b staining for normal PBMC samples by flow cytometry. Only CD45+/CD11b and CD45bright/CD11b+ cells are visible. B: Ratio of CD45+/CD11b to CD45+/CD11b+ cells for PBMCs and enhancing tumor specimens (GBMs). Marked differences are seen, suggesting that the CD45+ and CD11b+ cells in tumor specimens do not simply represent residual PBMCs. Each shape represents a tumor specimen taken from a specific patient.